Press "Enter" to skip to content

FDA warns API manufacturer involved in valsartan recall, provides information for patients taking these medications

FDA update on the ongoing investigation into angiotensin II receptor blocker impurities, recalls and current findings.

Original source:

Also Read:   Statement on efforts to help make development of biosimilar and interchangeable insulin products more efficient